Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]

[This corrects the article DOI: 10.1016/j.jtocrr.2022.100431.].

Uložené v:

Podrobná bibliografia
Vydané v:	JTO clinical and research reports Ročník 6; číslo 10; s. 100892
Hlavní autori:	Garassino, Marina C., Gadgeel, Shirish, Novello, Silvia, Halmos, Balazs, Felip, Enriqueta, Speranza, Giovanna, Hui, Rina, Garon, Edward B., Horinouchi, Hidehito, Sugawara, Shunichi, Rodriguez-Abreu, Delvys, Reck, Martin, Cristescu, Razvan, Aurora-Garg, Deepti, Loboda, Andrey, Lunceford, Jared, Kobie, Julie, Ayers, Mark, Piperdi, Bilal, Pietanza, M. Catherine, Paz-Ares, Luis
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 01.10.2025 Elsevier
Predmet:	Hematology, Oncology, and Palliative Medicine
ISSN:	2666-3643, 2666-3643
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	[This corrects the article DOI: 10.1016/j.jtocrr.2022.100431.].
Bibliografia:	erratum
ISSN:	2666-3643 2666-3643
DOI:	10.1016/j.jtocrr.2025.100892